Evotec SE ADR EVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Evotec Reports Results of the Annual General Meeting 2026
-
Evotec Appoints Rui Wang as Head of Global In Silico and AI
-
Evotec SE Successfully Placed €116.1 Million Convertible Bonds
-
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
-
Evotec Receives Grants to Advance Tuberculosis Treatment
-
Evotec Announces New Nomination to Board of Directors
-
Evotec SE to Announce First Quarter 2026 Results on May 6, 2026
-
Evotec Announces Chief Financial Officer Transition
Trading Information
- Previous Close Price
- $2.69
- Day Range
- $2.60–2.71
- 52-Week Range
- $2.31–4.42
- Bid/Ask
- $2.69 / $2.72
- Shares Outstanding
- 355.19M
- Market Cap
- $927.04M
- Volume/Avg
- 833 / 80,834
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.12
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.18%
Company Profile
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 4,553
- Website
- https://www.evotec.com
Valuation
|
Metric
|
EVO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.21 |
Price/Sales | 1.12 |
Price/Cash Flow | — |
Price/Earnings
EVO
Financial Strength
|
Metric
|
EVO
|
|---|---|
Quick Ratio | 1.49 |
Current Ratio | 1.68 |
Interest Coverage | −11.59 |
Quick Ratio
EVO
Profitability
|
Metric
|
EVO
|
|---|---|
Return on Assets (Normalized) | −7.32% |
Return on Equity (Normalized) | −15.96% |
Return on Invested Capital (Normalized) | −9.75% |
Return on Assets
EVO
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| ARYx Therapeutics Inc
ARYX
| — | Jcp | — | |||
| Merck KGaA
MKGAF
| — | Zjxgdp | $67B | |||
| Merck KGaA ADR
MKKGY
| Wvnzdxflbq | Hqwbhg | $67B | |||
| Galderma Group AG ADR
GALDY
| — | Sjjnk | $51B | |||
| Galderma Group AG Registered Shares
GDERF
| — | Bgmczt | $51B | |||
| Takeda Pharmaceutical Co Ltd
TKPHF
| — | Jjlp | $50B | |||
| Takeda Pharmaceutical Co Ltd ADR
TAK
| — | Rxxdk | $50B | |||
| Jiangsu Hengrui Pharmaceuticals Co Ltd ADR
JHPCY
| — | Dwhhgn | $47B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Mnwdrkmlw | Mbxfxbc | $40B | |||
| Teva Pharmaceutical Industries Ltd
TEVJF
| Jrlqlxqx | Xmgjyk | $40B |
United States